Methods. Setting-Urban Ryan White funded clinic in Columbia, SC providing care to about 2200 PLWH. A retrospective chart review was performed on a sample of patients ≥40 years old. Patients were eligible if they did not have a known diagnosis of ASCVD, had ≥ 3 visits in the last 3 years, and at least 1 visit in the past 12 months. Data regarding demographics, comorbidities, lab values, medications, and recent blood pressures were abstracted. Data were collected on assessment and intervention for smoking, weight loss, diet, and exercise. Objectives of this study were to: (1) determine the prevalence of ASCVD risk factors among patients without known ASCVD; (2) estimate the proportion of patients who received appropriate pharmacologic and lifestyle interventions.
Background. HIV infection has been associated with an increased risk of cardiovascular disease (CVD), stroke, and subclinical atherosclerosis in women. HIVpositive pre-menopausal women tend to lose the cardio-protective effect of estrogen and these women should be more vigilant in reducing their risk for developing CVD. Our study intends to assess the cardiovascular risk in the HIV-positive pre-menopausal women over the last 16 years (1999-2014) using a national wide sample.
Methods. This study is a cross-sectional study using the National Health and Nutrition Examination Survey (NHANES) datasets from 1999 to 2014. The 10-year Framingham risk score for developing CAD was calculated for the HIV-positive and HIV-negative pre-menopausal women. The individual risk factors contributing to CAD including blood pressure, hemoglobin A1c, c-reactive protein (CRP), smoking status, cholesterol level, family history of CVD were compared. The populations' intent to reduce their risk (exercise, diet modification and use of medications) and their doctor's advice to reduce the risk (counseling on diet, exercise and weight) were also analyzed. SPSS v.19 was used for analysis and p-value < 0.05 was considered significant.
Results. Out of the available sample of 82,091 people, 9635 women (11.7%) met the inclusion criteria (pre-menopausal women, 18 to 55 year old, no prior history of CAD, no missing data and tested for HIV). Among them, 25 women were HIV seropositive (0.25%). Though there was no significant difference in the systolic and diastolic blood pressure, HbA1c, CRP, HDL or total cholesterol (P > 0.05); the mean Framingham risk score in pre-menopausal HIV-positive women (M = 2.12, SD = 2.73) was significantly higher than the HIV-negative women (M = 0.95, SD = 1.94); P <0.01. Neither did majority of the HIV-positive women intend to decrease their cardiovascular risk nor did their health care providers advice them to do so.
Conclusion. This study shows that the risk of developing CVD in pre-menopausal women seems to be higher from the traditional risk factors itself. While HIV is now independent risk factor for developing CVD in women, more focus should be on reducing the risk from traditional methods like smoking cessation, diet and life style modification, blood pressure, diabetes and cholesterol and management.
Disclosures. All authors: No reported disclosures. Background. There are limited data on statin utilization among HIV+ individuals in real-world settings using the new 2013 ACC/AHA blood cholesterol guideline. We aimed to determine the proportion of appropriate statin use based on this guideline in a large urban outpatient center.
Statin Utilization Among Human-Immunodeficiency Virus (HIV)-Infected
Methods. Chart review of 1087 HIV+ patients 40 years and over from the Washington University Virology Clinic was done from January 1 to December 31, 2015. Patients were classified according to the 4 statin benefit groups from the guideline: (1) those with clinical atherosclerotic cardiovascular disease (ASCVD); (2) those with primary hyperlipidemia (LDL-C ≥ 190 mg/dL); (3) individuals 40 to 75 years of age with diabetes and an LDL 70 to 189 mg/dL without ASCVD; and (4) those 40 to 75 years of age without ASCVD or diabetes, with LDL 70 to 189 mg/dL, and with a 10-year ASCVD risk of ≥ 7.5%. Factors that may influence receipt of statin were analyzed using the chi-square test, t-test, or the Wilcoxon rank-sum test when applicable.
Results. The median age of patients was 51 years and the majority were male (71%), black (67%), receiving antiretroviral therapy (98%), had HIV RNA ≤ 20 copies/ ml (87%) and median CD4 count of 523 cells/µL. Overall, 450 (41%) patients had an indication for statin use, with the majority classified under group 4. However, only 160 (36%) were on statins, of whom 89% were on appropriate doses. The percentages of patients on statins were only 36%, 44%, 49%, and 30% for groups 1, 2, 3, and 4, respectively. There was no significant difference between those who were and were not on statins in terms of CD4 count and pill burden. The rates of ritonavir, cobicistat, and efavirenz use were also similar between the two groups. In group 4, however, those who had viral suppression were more likely to be prescribed a statin compared with those who had no viral suppression (95% vs. 87%, P = 0.031).
Conclusion. Two-thirds of our patients were not prescribed statins despite a strong indication for it based on the new guideline. Our finding stresses the critical
